RIOX1

Across TCGA pan-cancer cohorts, RIOX1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RIOX1’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where RIOX1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RIOX1 is over-expressed in tumor, although a few such as PDAC and CCRCC show the opposite, repressed pattern.

COAD, LUAD, and LSCC are the cancer types where RIOX1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RIOX1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	All	+0.281	<.001	10	view →
LUAD	Female	II,III,IV	+0.349	<.001	6	view →
LSCC	Male	All	+0.132	<.001	5	view →
PDAC	Female	All	−0.272	.002	4	view →
CCRCC	Male	III,IV	−0.108	.013	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RIOX1–COAD

Open the COAD breakdown →